MIFISO DIN 02533553
Status: Approved
Holder: LINEPHARMA INTERNATIONAL LIMITED
Health Canada record
| Active ingredient(s) | MIFEPRISTONE 200 MG; MISOPROSTOL 200 MCG |
|---|
| Dosage form | Kit; Tablet |
|---|
| Route | Oral; Buccal |
|---|
| Schedule | PRESCRIPTION |
|---|
| Class | Human |
|---|
| ATC | G03XB51 MIFEPRISTONE, COMBINATIONS |
|---|
| Original market date | |
|---|
| Current status date | 16-Dec-2022 |
|---|
| Source | Health Canada DPD |
|---|
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing MIFEPRISTONE
| DIN | Product | Company | Form | Strength | Status |
|---|
| 02560569 | FEMYSO | LUPIN PHARMA CANADA LIMITED | Tablet; Kit | MIFEPRISTONE 200 MG; MISOPROSTOL 200 MCG | Marketed |
| 02568055 | JAMP MIFEPRISTONE / MISOPROSTOL | JAMP PHARMA CORPORATION | Tablet | MIFEPRISTONE 200 MG; MISOPROSTOL 200 MCG | Approved |
| 02444038 | MIFEGYMISO | LINEPHARMA INTERNATIONAL LIMITED | Tablet; Kit | MIFEPRISTONE 200 MG; MISOPROSTOL 200 MCG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|
| 29717 | 2022-12-16 | New Drug Submission (NDS) | |
International API supply for MIFEPRISTONE
5 active FDA Drug Master Files.
Request a quote for MIFISO
How to read a Canadian DIN record